Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1

Conditions

Breast Neoplasms 109Neoplasms 99Lung Neoplasms 60Colorectal Neoplasms 45Prostatic Neoplasms 40Carcinoma, Non-Small-Cell Lung 39Pancreatic Neoplasms 33Melanoma 31Head and Neck Neoplasms 27Neoplastic Cells, Circulating 25Ovarian Neoplasms 24Uterine Cervical Neoplasms 20Sarcoma 19Multiple Myeloma 19Glioma 19Colonic Neoplasms 19Carcinoma, Hepatocellular 17Leukemia, Myeloid, Acute 16Neoplasm Metastasis 15Squamous Cell Carcinoma of Head and Neck 14Lymphoma 14Glioblastoma 14Esophageal Neoplasms 14Endometrial Neoplasms 14Leukemia 12Kidney Neoplasms 11Hematologic Neoplasms 11Gastrointestinal Neoplasms 11Carcinoma, Renal Cell 11Myelodysplastic Syndromes 10

Interventions

Rituximab 5fludarabine 4Tacrolimus 4Epoetin Alfa 4Cyclophosphamide 4Busulfan 4Darbepoetin alfa 3Alemtuzumab 3fludarabine phosphate 2entrectinib 2atezolizumab 2alectinib 2Thiotepa 2Therapeutics 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Methotrexate 2Etoposide 2Early Intervention, Educational 2Cytarabine 2Bortezomib 2Antilymphocyte Serum 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2venetoclax 1trametinib 1tirbanibulin 1sargramostim 1plerixafor 1phenethyl isothiocyanate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoproliferative Disorders × Blood Specimen Collection × Clear all
NCT01728402 2026-02-17

Pathogenesis of Hematologic Malignancies

OHSU Knight Cancer Institute

Enrolling by invitation
5,000 enrolled
LymphoidMyeloid

Lymphoproliferative Disorders, Myelodysplastic Syndromes, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡